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Chapter	III.	Manuscript		Dual	Opt-Out	Testing	for	Human	Immunodeficiency	Virus	(HIV)	and	Hepatitis	C	Virus	(HCV)	in	Primary	Care	Centers:	The	Time	Is	Now		Introduction		 There	are	an	estimated	3.2	million	people	living	in	the	U.S.	that	are	infected	with	hepatitis	C	virus	(HCV).7	About	75%	of	those	affected	are	unaware	of	their	infection.1	Due	to	the	often	symptom-less	nature	and	slow	progression	of	HCV,	those	infected	may	not	be	aware	of	their	infection	until	complications	from	the	disease	have	become	severe	and	available	treatment	options	have	become	limited.	From	2010-2015,	reported	cases	of	acute	HCV	infection	increased	more	than	2.9-fold,	rising	annually	throughout	this	period.2	Mortality	among	HCV-infected	persons-primarily	adults	aged	55-64	years-increased	during	2006-2010.	In	2013,	HCV-associated	deaths	exceeded	the	combined	number	of	deaths	with	60	other	infectious	diseases	as	underlying	causes.	Deaths	due	to	HCV	have	exceeded	deaths	related	to	human	immunodeficiency	virus/acquired	immunodeficiency	syndrome	(HIV/AIDS)	nationally	since	2007.1			 Although	HCV	is	a	considerable	burden	on	the	healthcare	sector,	funding	for	HCV	prevention	and	research	pales	in	comparison	to	funding	for	HIV	efforts,	even	though	an	estimated	20%	of	those	infected	with	HIV	are	co-infected	with	HCV.12	For	those	who	are	co-infected,	the	chance	of	liver-related	morbidity	and	mortality	is	higher,	even	when	the	HIV	infection	is	well	controlled.22	Co-infected	patients	account	for	93%	of	hepatocellular	carcinoma	cases	and	studies	have	reported	a	10-fold	increase	in	mortality	for	these	patients.23		 In	2012,	the	Centers	for	Disease	Control	and	Prevention	(CDC)	revised	HCV	screening	recommendations	to	include	one-time	testing	of	all	baby	boomers	and	screening	for	those	who	are	at	high	risk	for	infection.11	Screening	for	HCV	leads	to	early	diagnosis	and	thus	earlier	access	to	treatment,	more	treatment	options,	prevention	of	the	development	of	HCV-related	complications,	and	higher	linkage-to-care	success	rates.27	Despite	HCV	being	the	most	common	blood-borne	virus	in	the	US	and	the	substantial	scale	and	burden	of	the	disease,	routine	HCV	testing	is	not	uniformly	practiced.7	HCV	screening	rates	are	reported	
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to	be	as	low	as	54%	and	it	is	estimated	that	more	than	60%	of	individuals	who	have	received	a	diagnosis	are	not	engaged	in	care.11,41		 The	existing	literature	is	limited	to	only	a	few	Federally	Qualified	Health	Centers	(FQHCs)	and	the	implementation,	development,	and	evaluation	of	their	HIV	and	HCV	opt	out	testing	programs.	Opt-out	testing	is	done	after	the	patient	is	notified	that	the	test	will	be	performed.	Opt-out	testing	infers	that	a	patient	consents	to	being	tested,	unless	the	patient	specifically	asks	for	the	test	to	not	be	performed.	The	rationale	for	this	type	of	testing	is	that	it	enables	widespread	testing	that	can	identify	infections	earlier,	increase	the	number	of	people	who	do	not	know	they	are	infected,	reduce	stigma	associated	with	HIV	testing,	and	simplify	testing	because	written	consent	is	not	required.	These	clinics	represented	in	the	published	literature	are	in	large,	urban	cities	and	the	results	are	not	generalizable	to	other	locations	and	populations.	This	study	of	the	HIV/HCV	opt-out	program	of	Southside	Medical	Center	(SMC)	adds	to	the	prior	literature	by	reinforcing	the	success	of	routine	opt-out	testing.	Because	SMC	is	an	access	point	for	over	30,000	people	across	rural	and	urban	counties	in	Georgia,	this	study	presents	additional	data	that	has	not	been	thoroughly	studied.		The	aims	of	our	study	were	to	evaluate	the	prevalence	of	HIV	and	HCV	screening	prior	to	and	following	the	implementation	of	a	dual	routine	opt-out	program,	the	linkage	to	care	practices	for	positive	patients,	and	the	demographic	characteristics	of	positive	patients	in	a	southern	FQHC.			Methods	We	conducted	a	retrospective,	cross-sectional	study	using	electronic	health	record	(EHR)	data	from	patients	receiving	care	at	the	Southside	Medical	Center	(SMC)	in	Atlanta,	Georgia.	The	EHR	system	allows	patient-level	data	to	be	extracted	across	all	clinic	sites	from	2012-2017.	Medical	records	created	prior	to	2012	were	not	available	for	this	study.	Approval	from	the	Georgia	State	University	Institutional	Review	Board	was	obtained	prior	to	study	start.		Diagnostic	codes	from	the	9th	and	10th	revisions	of	the	International	Classification	of	Disease,	Clinical	Modification	(ICD-CM)	were	used	to	find	cases.	The	use	of	ICD	9	codes	first	
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began	in	1979,	and	continued	at	SMC	until	September	30,	2015.	The	current	coding	system	is	ICD	10,	which	began	on	October	1,	2015.42	Inclusion	criteria	for	HIV+	patients	were:	13-64	years	of	age,	treatment	at	one	of	the	10	SMC	clinics,	and	a	diagnosis	of	HIV	infection	using	ICD	9	CM	diagnostic	code	042	and	ICD	10	CM	diagnostic	code	B20.	B20	human	immunodeficiency	virus	(HIV)	disease	includes:	acquired	immune	deficiency	syndrome	(AIDS),	AIDS-related	complex	(ARC),	HIV	infection,	symptomatic.	Inclusion	criteria	for	HCV+	patients	were:	18	years	of	age	and	older,	treatment	at	one	of	the	10	SMC,	and	a	diagnosis	of	HCV	using	ICD	9	CM	diagnostic	codes	070.41:	acute	hepatitis	C	with	hepatic	coma,	070.44:	chronic	hepatitis	C	with	hepatic	coma,	070.51:	acute	hepatitis	C	without	mention	of	hepatic	coma,	070.54:	chronic	hepatitis	C	without	mention	of	hepatic	coma,	and	070.7:	unspecified	viral	hepatitis	C,	and	ICD	10	CM	diagnostic	codes	B17.1:	acute	hepatitis	C,	B18.2:	chronic	viral	hepatitis	C,	and	B19.2:	unspecified	viral	hepatitis	C.	Inclusion	criteria	for	co-infected	HIV+/HCV+	patients	were	the	same	as	the	criteria	detailed	above.	The	year	in	which	the	case	was	counted	depended	on	the	earliest	known	date	for	the	secondary	infection.	The	earliest	diagnostic	dates	for	each	of	the	infections	were	counted	in	the	year	in	which	they	occurred,	so	that	a	co-infected	patient	was	counted	3	times:	as	a	case	for	the	year	in	which	an	HIV+	diagnosis	first	occurred,	as	a	case	for	the	year	in	which	an	HCV+	diagnosis	first	occurred,	and	as	a	case	for	the	year	in	which	a	secondary	infection	diagnosis	first	occurred.		Pre-HIV/HCV	opt-out	testing	implementation	was	defined	as	a	positive	HIV	or	HCV	diagnosis	between	June	2012	and	February	2014.	Post-HIV/HCV	opt-out	testing	implementation	was	defined	as	a	positive	HIV	or	HCV	diagnosis	between	March	2014	and	July	2017.	All-tested	refers	to	all	eligible	patients	who	consented	to	being	tested	for	either	HIV	or	HCV.	The	patient-level	demographic	data	that	were	collected	included	date	of	birth,	age,	sex,	race,	and	ethnicity.	The	EHR	data	was	de-identified	and	unduplicated	prior	to	analysis.	Linkage	to	care	was	defined	as	a	patient	attending	an	appointment	with	a	prescribing	provider	within	30	days	of	the	diagnosis.			Results	
Pre-HIV/HCV	opt-out	implementation		
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SMC	conducted	9,906	HIV	tests	prior	to	HIV/HCV	opt-out	testing	implementation.	The	number	of	HCV	tests	conducted	during	the	pre-HIV/HCV	opt-out	testing	implementation	could	not	be	analyzed,	due	to	multiple	software	updates	and	a	lack	of	documentation	of	HCV	during	this	time.			 There	were	68	patients	identified	as	HIV+.	Sixty-six	of	these	patients	were	linked	to	care	(97.05%).	Of	the	68	diagnosed	with	HIV,	95.59%	were	African	American,	98.53%	were	non-Hispanic,	and	62.50%	were	male.	Thirty-seven	percent	of	these	patients	were	aged	41-50,	25%	were	aged	31-40,	25%	were	aged	51-90,	and	12.5%	were	aged	23-30.	There	were	89	patients	identified	as	HCV+.	Of	these	patients,	67.42%	were	black/African	American,	15.73%	were	white,	11.24%	declined	to	answer,	1.12%	were	unknown,	and	4.49%	were	Asian.	The	majority	of	patients	were	non-Hispanic	(97.75%).	53.93%	were	male	and	46.07%	were	female.	The	age	range	of	HCV+	patients	showed	that	most	patients	were	50-59	years	of	age	or	60-60	years	of	age:	33.71%	and	38.31%,	respectively.	There	was	no	information	about	linkage-to-care	nor	data	on	HCV	Ab	total	tested	prior	to	March	2014.		There	were	3	HCV/HIV	co-infected	patients	identified	prior	to	routine	opt-out	testing.	All	3	patients	were	Black/African	American	and	non-Hispanic.	Two	patients	were	male;	1	was	female.	Their	ages	were	35,	63,	and	57	years	old.	Two	of	the	patients	had	a	primary	diagnosis	of	HIV	and	a	secondary	diagnosis	of	HCV.	The	third	patient	was	diagnosed	with	both	on	the	same	day.	All	three	patients	were	linked	to	care	with	a	referral	to	external	organizations.	This	was	due	to	SMC	not	having	an	Infectious	Disease	clinic	at	that	time.			
Post-HIV/HCV	opt-out	implementation	SMC	conducted	38,283	HIV	tests	and	19,308	HCV	tests	after	HIV/HCV	opt-out	testing	implementation.	There	were	232	HIV+	patients	identified	during	this	time	period.	There	was	a	successful	linkage	to	care	rate	of	96.98%.	Of	the	232	patients	diagnosed	with	HIV,	the	majority	were	African	American	(82.33%)	and	non-Hispanic	(93.53%).	Males	comprised	58.19%	of	the	population.	Patients	were	nearly	evenly	distributed	amongst	the	following	age	categories:	51-90	(28.45%),	23-30	(27.59%),	and	31-40	(21.98%).		
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There	were	274	HCV+	patients	identified	during	this	time	period.	Of	these	patients,	52.92%	were	Black/African	American,	94.89%	were	non-Hispanic,	55.84%	were	male,	and	79.71%	were	linked	to	care.	45.99%	were	60-69	years	of	age	and	31.39%	were	50-59	years	old.	The	other	age	groups	were	as	follows:	9.49%	were	40-49	years	of	age,	5.11%	were	30-39	years	of	age,	4.01%	were	18-29	years	of	age,	and	4.01%	were	equal	to	or	older	than	70	years	of	age.		There	were	13	co-infected	patients	identified	during	this	time.	Of	these	patients,	76.9%	were	male,	61.53%	were	Black/African	American,	92.30%	were	non-Hispanic,	and	61.53%	were	in	the	birth	cohort.	Five	patients	(38.46%)	received	both	diagnoses	concurrently.	Four	patients	had	a	primary	diagnosis	of	HCV,	and	four	patients	had	a	primary	diagnosis	of	HIV.		Eleven	patients	were	linked	to	care.			Discussion		The	HIV	and	HCV	patient	populations	remained	consistent	both	before	and	after	implementation	in	regards	to	demographic	distribution.	These	demographics	reflect	the	general	population	of	the	patients	SMC	serves:	non-Hispanic	African	Americans.33	The	age	distribution	of	the	HCV+	patients	at	SMC	matched	the	trends	seen	nationwide	for	patients	belonging	to	the	1945-1965	birth	cohort.		Comparing	the	amount	of	tests	performed	during	the	pre-HIV/HCV	opt	out	testing	period	to	the	post-HIV/HCV	opt	out	testing	period,	shows	a	286%	increase	for	HIV	tests.	The	increase	in	HIV/HCV	testing	may	partly	be	due	to	the	hiring	of	an	Infectious	Disease	specialist	in	2015.	Referrals	to	external	organizations	for	HIV/HCV	positive	patients	may	take	longer,	require	more	work	and	coordination,	and	have	poor	follow	up.	Internal	referrals	to	the	infectious	disease	department	happened	the	same	day	as	the	diagnosis,	which	some	providers	opting	to	personally	call	the	infectious	disease	clinic	to	refer	the	patient.	SMC	has	fully	incorporated	infectious	disease	into	the	primary	care	environment.	An	infectious	disease	specialist	works	alongside	adult	medicine	providers,	pediatricians,	pharmacists,	OBGYNs,	and	counselors.	There	is	an	onsite	lab	at	each	facility	that	allows	patients	to	see	the	provider	and	get	lab	work	done	immediately	after.	This	comprehensive	
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system	simplifies	and	lessens	the	burden	put	on	patients	to	keep	up	with	their	medications,	diagnoses,	lab	work,	and	appointments.		The	linkage	to	care	rates	for	HIV+	and	HCV+	patients	were	higher	than	those	of	other	studies	and	guidelines.	The	national	HIV	linkage	to	care	goal,	set	by	the	federal	government,	is	at	least	85%	of	persons	linked	to	HIV	medical	care	within	30	days	of	diagnosis.43	For	HIV+	patients,	the	percentages	were	>95%	during	both	time	periods.	The	HCV	linkage	to	care	rate	of	the	post-opt	out	period	(79.71%)	was	also	greater	than	those	found	in	similar	studies	by	Coyle	et	al.	(38.7%	and	66.1%).7,12	Several	barriers	were	identified	during	implementation	of	the	testing	program	and	during	analysis	of	the	available	data.	The	lack	of	access	to	digitized	medical	records	prevented	an	in-depth	look	at	the	actual	prevalence	of	HIV	and	HCV	infection	in	the	patient	population	during	the	years	when	paper	records	were	used.	Complete	records	are	needed	to	fully	demonstrate	the	significance	of	routine	opt-out	testing,	and	resources	should	be	allocated	to	improve	and	update	electronic	health	databases.	In	going	forward	with	new	EHR	software,	health	centers	should	make	it	a	priority	that	patient	information	not	be	lost	when	moving	to	a	different	program.		Additionally,	patient	contact	information	should	be	checked	and	updated	at	every	visit	to	guarantee	that	the	most	up-to-date	information	is	available	for	linkage	to	care	efforts.	Making	patients	aware	of	available	transportation,	prescription	assistance	programs,	and	sliding	scale	pay	fees	should	also	be	of	utmost	importance	during	the	initial	visit.	These	changes	require	financial	resources	and	additional	staffing	that	many	may	not	have	access	to.	To	mitigate	this	issue,	FQHCs	could	train	staff	who	work	in	medical	records	to	transition	the	practice	over	to	digital	medical	records.		SMC	was	able	to	successfully	implement	routine	opt-out	testing	thanks	to	considerable	efforts	to	initiate	and	support	an	Infectious	Disease	(ID)	Clinic	within	the	health	center.	Including	a	separate	ID	Clinic	allowed	providers	and	staff	to	give	focused	care	to	HIV	and	HCV	infected	patients	in	a	smaller,	more	individualized	setting.	The	unique	one-stop	shop	method	at	SMC	enables	patients	to	receive	primary	care	from	their	PCP,	and	then	move	to	ID	treatment	with	an	ID	specialist,	then	to	the	pharmacy	for	any	prescription	needs	with	ease.	This	setting	limits	the	amount	of	trips	one	patient	will	need	to	make	for	
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health	care	which	alleviates	stress	and	the	hassle	of	keeping	track	of	several	appointment	dates	and	times.			Limitations	Our	study	had	several	limitations.	First,	the	population	receiving	primary	care	at	SMC	is	primarily	Black/African	American,	low	socioeconomic	status,	and	uninsured	and	underinsured;	thus,	our	results	may	not	be	generalizable	to	other	populations.	Similarly,	SMC	is	a	community	health	center	located	in	Atlanta,	a	highly	populated	city	in	the	southern	US,	and	the	results	shown	here	may	not	apply	to	other	cities	or	types	of	health	services	across	the	country.	Second,	due	to	high	staff	turnover,	there	is	no	way	to	know	if	providers	are	reliably	moving	through	the	opt-out	prompts	with	the	patients.		There	is	a	lag	in	opt-out	training	for	the	newly	on-boarded	staff,	leading	to	inconsistent	offering	of	opt-out	testing.	Third,	due	to	SMC’s	variability	of	being	a	primary	care	facility	for	some	and	a	walk-in	clinic	for	others,	some	patients	testing	positive	may	have	different	primary	care	providers	outside	of	SMC	and	thus	could	have	been	linked	to	care	elsewhere.			Conclusions	Southside	Medical	Center	is	in	a	unique	position	as	a	community	health	program	located	in	Atlanta,	a	highly	populated	southern	city	facing	the	HIV	epidemic.	SMC’s	development	and	implementation	of	routine	dual	HCV/HIV	opt-out	screening	programs	should	serve	as	an	example	to	other	health	centers	looking	to	improve	care	outcomes	for	patients	living	with	and	at	risk	for	HIV	and	HCV,	as	well	as	the	general	population’s	healthcare	as	a	whole.			 	
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